Deucravacitinib Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 6 mg

Reference Brands: Sotyktu (USA/EU)

Category: Immune Disorder

Product Description:

Deucravacitinib is an oral targeted therapy used for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It belongs to a newer class of small-molecule medicines known as tyrosine kinase 2 (TYK2) inhibitors. By selectively blocking the TYK2 pathway, deucravacitinib helps regulate immune signaling involved in inflammatory skin disease, leading to reduced plaque formation, redness, and scaling. Its selective mechanism allows more focused immune modulation compared with broader immunosuppressive treatments.

The medicine is taken once daily by mouth, which offers a convenient dosing approach and can support better patient adherence compared to injectable therapies. Clinical studies have shown meaningful improvement in skin clearance and symptom control in many patients with plaque psoriasis. Deucravacitinib is generally prescribed under specialist supervision, with monitoring for potential adverse effects and drug interactions. It is marketed under the brand name Sotyktu and was developed by Bristol Myers Squibb. The product is approved in several major markets for systemic psoriasis treatment.